| . | Improvement or stability of IBD-DI (ΔIBD-DI ≤0) (n = 61) . | Worsening of IBD-DI (ΔIBD-DI >0) (n = 37) . | P value . |
|---|---|---|---|
| Female | 60.7% | 64.9% | .68 |
| Median age at diagnosis, y | 21.2 | 24.9 | .01 |
| Median age at inclusion, y | 34 | 37.9 | .13 |
| Median CD duration at IBD-DI 1, y | 11 | 11 | .7 |
| Current smoker | 31% | 36.1% | .68 |
| Median LI 1 | 9 | 8.1 | .78 |
| Upper tract location | 4.9% | 10.8% | .49 |
| Small bowel location | 95.1% | 100% | .44 |
| Colonic location | 42.6% | 48.6% | .56 |
| Anal location | 39.3% | 21.6% | .07 |
| Phenotype B1 | 44.3% | 27% | .1 |
| Extradigestive manifestations | 14.7% | 10.8% | .58 |
| Articular manifestations | 85.2% | 89.2% | .32 |
| Previous biologic exposure > 2 | 9.8% | 5.4% | .63 |
| Previous anti-TNF exposure | 67.2% | 70.3% | .75 |
| Previous combination therapy exposure | 63.9% | 64.9% | .92 |
| Current combination therapy exposure | 21.3% | 5.4% | .03 |
| Previous surgery | 57.4% | 51.3% | .56 |
| New resection between IBD-DI 1 and 2 | 8.2% | 2.7% | .27 |
| Clinical disease activity (HBI or PGA) | 42.6% | 35.1% | .46 |
| Mean CRP level at assessment 2, mg/L | 3.1 | 6 | .16 |
| Mean fecal calprotectin at IBD-DI 2, mg/kg | 209 | 335 | .8 |
| Dose escalation | 39.3% | 16% | .016 |
| Use of steroids between IBD-DI 1 and 2 | 9.8% | 8.1% | .77 |
| Change of biologic between IBD-DI 1 and 2 | 27.9% | 27% | .93 |
| . | Improvement or stability of IBD-DI (ΔIBD-DI ≤0) (n = 61) . | Worsening of IBD-DI (ΔIBD-DI >0) (n = 37) . | P value . |
|---|---|---|---|
| Female | 60.7% | 64.9% | .68 |
| Median age at diagnosis, y | 21.2 | 24.9 | .01 |
| Median age at inclusion, y | 34 | 37.9 | .13 |
| Median CD duration at IBD-DI 1, y | 11 | 11 | .7 |
| Current smoker | 31% | 36.1% | .68 |
| Median LI 1 | 9 | 8.1 | .78 |
| Upper tract location | 4.9% | 10.8% | .49 |
| Small bowel location | 95.1% | 100% | .44 |
| Colonic location | 42.6% | 48.6% | .56 |
| Anal location | 39.3% | 21.6% | .07 |
| Phenotype B1 | 44.3% | 27% | .1 |
| Extradigestive manifestations | 14.7% | 10.8% | .58 |
| Articular manifestations | 85.2% | 89.2% | .32 |
| Previous biologic exposure > 2 | 9.8% | 5.4% | .63 |
| Previous anti-TNF exposure | 67.2% | 70.3% | .75 |
| Previous combination therapy exposure | 63.9% | 64.9% | .92 |
| Current combination therapy exposure | 21.3% | 5.4% | .03 |
| Previous surgery | 57.4% | 51.3% | .56 |
| New resection between IBD-DI 1 and 2 | 8.2% | 2.7% | .27 |
| Clinical disease activity (HBI or PGA) | 42.6% | 35.1% | .46 |
| Mean CRP level at assessment 2, mg/L | 3.1 | 6 | .16 |
| Mean fecal calprotectin at IBD-DI 2, mg/kg | 209 | 335 | .8 |
| Dose escalation | 39.3% | 16% | .016 |
| Use of steroids between IBD-DI 1 and 2 | 9.8% | 8.1% | .77 |
| Change of biologic between IBD-DI 1 and 2 | 27.9% | 27% | .93 |
Abbreviations: CD, Crohn’s disease; HBI, Harvey-Bradshaw index; IBD-DI, Inflammatory Bowel Disease Disability Index; LI, Lémann index; PGA, physician global assessment; TNF, tumor necrosis factor.
| . | Improvement or stability of IBD-DI (ΔIBD-DI ≤0) (n = 61) . | Worsening of IBD-DI (ΔIBD-DI >0) (n = 37) . | P value . |
|---|---|---|---|
| Female | 60.7% | 64.9% | .68 |
| Median age at diagnosis, y | 21.2 | 24.9 | .01 |
| Median age at inclusion, y | 34 | 37.9 | .13 |
| Median CD duration at IBD-DI 1, y | 11 | 11 | .7 |
| Current smoker | 31% | 36.1% | .68 |
| Median LI 1 | 9 | 8.1 | .78 |
| Upper tract location | 4.9% | 10.8% | .49 |
| Small bowel location | 95.1% | 100% | .44 |
| Colonic location | 42.6% | 48.6% | .56 |
| Anal location | 39.3% | 21.6% | .07 |
| Phenotype B1 | 44.3% | 27% | .1 |
| Extradigestive manifestations | 14.7% | 10.8% | .58 |
| Articular manifestations | 85.2% | 89.2% | .32 |
| Previous biologic exposure > 2 | 9.8% | 5.4% | .63 |
| Previous anti-TNF exposure | 67.2% | 70.3% | .75 |
| Previous combination therapy exposure | 63.9% | 64.9% | .92 |
| Current combination therapy exposure | 21.3% | 5.4% | .03 |
| Previous surgery | 57.4% | 51.3% | .56 |
| New resection between IBD-DI 1 and 2 | 8.2% | 2.7% | .27 |
| Clinical disease activity (HBI or PGA) | 42.6% | 35.1% | .46 |
| Mean CRP level at assessment 2, mg/L | 3.1 | 6 | .16 |
| Mean fecal calprotectin at IBD-DI 2, mg/kg | 209 | 335 | .8 |
| Dose escalation | 39.3% | 16% | .016 |
| Use of steroids between IBD-DI 1 and 2 | 9.8% | 8.1% | .77 |
| Change of biologic between IBD-DI 1 and 2 | 27.9% | 27% | .93 |
| . | Improvement or stability of IBD-DI (ΔIBD-DI ≤0) (n = 61) . | Worsening of IBD-DI (ΔIBD-DI >0) (n = 37) . | P value . |
|---|---|---|---|
| Female | 60.7% | 64.9% | .68 |
| Median age at diagnosis, y | 21.2 | 24.9 | .01 |
| Median age at inclusion, y | 34 | 37.9 | .13 |
| Median CD duration at IBD-DI 1, y | 11 | 11 | .7 |
| Current smoker | 31% | 36.1% | .68 |
| Median LI 1 | 9 | 8.1 | .78 |
| Upper tract location | 4.9% | 10.8% | .49 |
| Small bowel location | 95.1% | 100% | .44 |
| Colonic location | 42.6% | 48.6% | .56 |
| Anal location | 39.3% | 21.6% | .07 |
| Phenotype B1 | 44.3% | 27% | .1 |
| Extradigestive manifestations | 14.7% | 10.8% | .58 |
| Articular manifestations | 85.2% | 89.2% | .32 |
| Previous biologic exposure > 2 | 9.8% | 5.4% | .63 |
| Previous anti-TNF exposure | 67.2% | 70.3% | .75 |
| Previous combination therapy exposure | 63.9% | 64.9% | .92 |
| Current combination therapy exposure | 21.3% | 5.4% | .03 |
| Previous surgery | 57.4% | 51.3% | .56 |
| New resection between IBD-DI 1 and 2 | 8.2% | 2.7% | .27 |
| Clinical disease activity (HBI or PGA) | 42.6% | 35.1% | .46 |
| Mean CRP level at assessment 2, mg/L | 3.1 | 6 | .16 |
| Mean fecal calprotectin at IBD-DI 2, mg/kg | 209 | 335 | .8 |
| Dose escalation | 39.3% | 16% | .016 |
| Use of steroids between IBD-DI 1 and 2 | 9.8% | 8.1% | .77 |
| Change of biologic between IBD-DI 1 and 2 | 27.9% | 27% | .93 |
Abbreviations: CD, Crohn’s disease; HBI, Harvey-Bradshaw index; IBD-DI, Inflammatory Bowel Disease Disability Index; LI, Lémann index; PGA, physician global assessment; TNF, tumor necrosis factor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
